A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Exclusion Criteria

• •Diagnosis of PH WHO Groups 2, 3, 4, or 5
• •Diagnosis of the following PAH Group 1 subtypes:
• •* Human immunodeficiency virus (HIV)-associated PAH
• •* PAH associated with portal hypertension
• •* Schistosomiasis-associated PAH
• •* PAH with features of significant venous/capillary pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) involvement
• •Is on the waiting list for lung transplant
• •Pregnant or breastfeeding women
• •History of full or partial pneumonectomy
• •Pulmonary function test (PFT) values of forced vital capacity (FVC) \< 60% predicted at the screening visit or within 6 months prior to the screening visit.
• •Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the screening visit or planned initiation during the study.
• •History of more than mild obstructive sleep apnea that is untreated
• •Known history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication), defined as mild to severe hepatic impairment.
• •History of restrictive, constrictive, or congestive cardiomyopathy.
• •History of atrial septostomy within 180 days prior to the screening visit.
• •Personal or family history of long QT syndrome (LQTS) or sudden cardiac death.
• •Left ventricular ejection fraction (LVEF) \< 45% on historical Echocardiogram (ECHO) within 6 months prior to the screening visit.
• •Any symptomatic coronary disease events within 6 months prior to the screening visit.
• •Cerebrovascular accident within 3 months prior to the screening visit.
• •Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease, mitral stenosis and more than mild aortic valve stenosis.
• •Prior exposure to sotatercept or luspatercept or history of allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients in investigational product
• •Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, vasopressin) within 30 days prior to the screening visit
• •Currently enrolled in or have completed any other investigational product study within 30 days
• •Weight at the screening is over 85 kg